Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)

被引：0
|
作者：
Giagounidis, A. [1 ]
Ades, L. [2 ]
Watts, J. [3 ]
Radinoff, A. [4 ]
Arnan Sangerman, M. [5 ]
Cerrano, M. [6 ]
Font Lopez, P. [7 ]
Zeidner, J. [8 ]
Diez Campelo, M. [9 ,10 ]
Graux, C. [11 ]
Liesveld, J. [12 ]
Selleslag, D. [13 ]
Tzvetkov, N. [14 ]
Fram, R. J. [15 ]
Zhao, D. [15 ]
Bell, J. [15 ]
Friedlander, S. [15 ]
Faller, D. V. [15 ]
Sekeres, M. A. [16 ]
机构：
[1] Marien Hosp, Klin Onkol Hamatol & Palliat Med, Dusseldorf, Germany
[2] Hop St Louis, Paris, France
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Hosp Sveti Ivan Rislki, Sofia, Bulgaria
[5] Inst Catala Oncol Inst Invest Biomed Bellvitge ID, Barcelona, Spain
[6] Univ Turin, Div Hematol, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
[8] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[9] Univ Hosp Salamanca HUS IBSAL, Dept Hematol, CIBERONC, Salamanca, Spain
[10] Ctr Canc Res IBMCC USAL CSIC, Salamanca, Spain
[11] Catholic Univ Louvain, Ctr Hosp Univ, Namur, Belgium
[12] Univ Rochester, James P Wilmot Canc Inst, Rochester, NY 14627 USA
[13] AZ Sint Jan Brugge Oostende, Brugge, Belgium
[14] MHAT Dr Georgi Stranski, Clin Haematol, Pleven, Bulgaria
[15] Millennium Pharmaceut Inc, Cambridge, MA USA
[16] Cleveland Clin, Cleveland, OH 44106 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
653
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [31] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [32] Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Borthakur, Gautam
    Konopleva, Marina
    Ravandi, Farhad
    Wierda, William G.
    Estrov, Zeev
    Faderl, Stefan
    Kadia, Tapan
    Rey, Kristy
    Cheung, Cora
    Kantajian, Hagop M.
    BLOOD, 2011, 118 (21) : 1122 - 1122
  • [33] Additional Analyses of a Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117
    Sekeres, Mikkael A.
    Othus, Megan
    List, Alan F.
    Odenike, Olatoyosi
    Stone, Richard M.
    Gore, Steven D.
    Litzow, Mark R.
    Buckstein, Rena
    Fang, Min
    Roulston, Diane
    Bloomfield, Clara D.
    Zhang, Yanming
    Velasco, Mario R.
    Gaur, Rakesh
    Atallah, Ehab
    Attar, Eyal C.
    Appelbaum, Frederick R.
    Erba, Harry P.
    BLOOD, 2015, 126 (23)
  • [34] A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
    Mikkael A. Sekeres
    Michael Schuster
    Magalie Joris
    Jürgen Krauter
    Johan Maertens
    Dimitri Breems
    Emmanuel Gyan
    Tibor Kovacsovics
    Amit Verma
    Paresh Vyas
    Eunice S. Wang
    Keith Ching
    Thomas O’Brien
    Corrado Gallo Stampino
    Weidong Wendy Ma
    Arthur Kudla
    Geoffrey Chan
    Amer M. Zeidan
    Annals of Hematology, 2022, 101 : 1689 - 1701
  • [35] RANDOMIZED PHASE 2 STUDY OF GUADECITABINE IN PATIENTS WITH HMA-NAIVE HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Savona, M. R.
    Garcia-Manero, G.
    Roboz, G. J.
    Walsh, K. J.
    Kropf, P. L.
    Issa, J. P.
    O'Connell, C. L.
    Tibes, R.
    Yee, K. W. L.
    Stock, W.
    Lunin, S.
    Berdeja, J. G.
    Naim, S.
    Hao, Y.
    Azab, M.
    Kantarjian, H.
    LEUKEMIA RESEARCH, 2017, 55 : S40 - S41
  • [36] Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia
    Mozessohn, Lee
    Cheung, Matthew C.
    Mittmann, Nicole
    Earle, Craig C.
    Liu, Ning
    Buckstein, Rena
    JCO ONCOLOGY PRACTICE, 2021, 17 (04) : E517 - E525
  • [37] An Open-Label, Multicenter, Phase Ib Study of the Anti-TIM3 Monoclonal Antibody BC3402 in Combination with Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
    Li, Bing
    Yin, Qing-song
    Yan, Xiaojing
    Hang, Min
    Guo, Hai-Jun
    Wang, Sheng
    Wang, Yi-wei
    Hei, Yong-jiang
    Xiao, Zhi-jian
    BLOOD, 2024, 144 : 4135 - 4136
  • [38] A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
    Sebert, Marie
    Renneville, Aline
    Bally, Cecile
    Peterlin, Pierre
    Beyne-Rauzy, Odile
    Legros, Laurence
    Gourin, Marie-Pierre
    Sanhes, Laurence
    Wattel, Eric
    Gyan, Emmanuel
    Park, Sophie
    Stamatoullas, Aspasia
    Banos, Anne
    Laribi, Kamel
    Jueliger, Simone
    Bevan, Luke
    Chermat, Fatiha
    Sapena, Rosa
    Nibourel, Olivier
    Chaffaut, Cendrine
    Chevret, Sylvie
    Preudhomme, Claude
    Ades, Lionel
    Fenaux, Pierre
    HAEMATOLOGICA, 2019, 104 (08) : 1565 - 1571
  • [39] A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612
    Assouline, Sarit
    Michaelis, Laura C.
    Othus, Megan
    Hay, Annette E.
    Walter, Roland B.
    Jacoby, Meagan A.
    Schroeder, Mark A.
    Uy, Geoffrey L.
    Law, Lisa Y.
    Cheema, Faisal
    Sweet, Kendra L.
    Asch, Adam S.
    Liu, Jijun
    Moseley, Anna B.
    Maher, Tracy
    Kingsbury, Laura L.
    Fang, Min
    Radich, Jerald
    Little, Richard F.
    Erba, Harry P.
    LEUKEMIA & LYMPHOMA, 2023, 64 (02) : 473 - 477
  • [40] Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia
    Bell, Jill A.
    Galaznik, Aaron
    Pompilus, Farrah A.
    Strzok, Sara
    Fram, Robert J.
    Faller, Douglas V.
    Marquis, Patrick
    BLOOD, 2017, 130
12345